Integra LifeSciences Q3 adjusted EPS seen at $0.55-$0.59; revenue seen at $410-$412 million

By Public Technologies
  • Integra LifeSciences expects Q3 2026 revenue of about $410 million-$412 million; adjusted EPS seen at $0.55-$0.59.
  • Flooding-related supply disruption is estimated to have reduced Q3 revenue by about $7 million; Q4 revenue hit seen at $15 million-$20 million.
  • Full-year 2026 revenue outlook cuts to $1.634 billion-$1.654 billion; adjusted EPS guidance lowered to $2.30-$2.40.
  • Operating cash flow still projected at about $190 million-$200 million for 2026; Q3 operating cash flow expected above $85 million.
  • Cincinnati site expected to return to full manufacturing operations in Q2 2027; insurance recoveries expected to offset a substantial portion of earnings impact.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020805PRIMZONEFULLFEED9838446) on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.